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ABSTRACT 
Hypotheses concerning paradoxical, psychostimulant-related side effects experienced by 
ADHD children were examined in the context of a double-blind, placebo-controlled, within 
subject (crossover) experimental design. Results revealed that behavioral and physical 
complaints were significantly higher under baseline relative to placebo and the four 
methylphenidate (MPH) conditions (5-mg, 10-mg, 15-mg, 20-mg) across three symptom 
categories: ADHD core/secondary symptoms, symptoms common to all children, and symptoms 
highly specific to MPH. No significant differences were found among active drug conditions. 
Implications of these findings for assessing and monitoring potential treatment emergent 
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW 
Attention Deficit Hyperactivity Disorder (ADHD) is a complex and chronic disorder of 
brain, behavior, and development whose behavioral and cognitive consequences pervade 
multiple areas of functioning. Core features of the disorder involve difficulties with attention, 
impulsiveness, and hyperactivity (DSM-IV, 1994), and are hypothesized to affect behavioral and 
cognitive functioning to the extent that the latter are dependent upon the former for successful 
execution (Rapport, Chung, Shore, & Issacs, 2001). 
Treatment of attention deficits traditionally involves using behavior or pharmacological 
therapy alone or in combination (for reviews, see Conners, Epstein, & March, 2001; Jensen, 
1999; Pelham et al., 1998; Swanson, McBurnett, Christian, & Wigal, 1995). Pharmacological 
interventions (and particularly the psychostimulants), however, are generally considered more 
cost effective and have the added benefit of affecting both behavioral and cognitive domains 
throughout the day without the specific programming and oversight required by behavior therapy 
(Douglas, Barr, O’Neil, & Britton, 1985; DuPaul & Eckert, 1997; Gittelman-Klein & Klein, 
1976; MTA Cooperative Group, 1999). Methylphenidate (MPH) is by far the most commonly 
prescribed pharmacological treatment for ADHD (Faraone, Biederman, & Roe, 2002; Grcevich, 
Rowane, Marcellino, & Sullivan-Hurst, 2001; Jensen et al., 1999; Swanson & Volkow, 2002), 
and its reputation is well deserved based on traditional benchmarks such as the breadth of 
effectiveness and overall response rate among affected individuals.  
Beneficial effects are observed across multiple domains of functioning based on direct 
observations of children’s attention, behavior and academic performance (Barkley, 1977; 
Cunningham, Seigel, & Offord, 1985; Douglas, Barr, O’Neil, & Britton, 1985; DuPaul & 
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Rapport, 1993; Rapport, Denney, DuPaul, & Gardner, 1994), parent and teacher ratings of social 
deportment (DuPaul et al., 1993; Fischer & Newby, 1991; Musten, Firestone, Pisterman, 
Bennett, & Mercer, 1997; MTA Cooperative Group, 1999), and objective performance indices 
associated with a wide range of clinic-based neurocognitive tests, tasks, and paradigms (for 
reviews, see Denney & Rapport, 2001; Losier, McGrath, & Klein, 1996; Rapport & Kelley, 
1991). Peer relationships and interpersonal behavior (Barkley, Karlsson, Pollard, & Murphy, 
1985; Cunningham, Seigel, & Offord, 1991; Cunningham et al., 1985; Humphries, Kinsbourne, 
& Swanson, 1978; Smith et al., 1998; Whalen et al., 1989), and even performance during 
extracurricular activities such as playing baseball (Pelham et al., 1990), may improve as a 
function of treatment. Treatment response rates are remarkable and estimated to range between 
50% and 96% depending on the stringency with which positive response is defined and the 
nature of the targeted outcome variable (Barkley, 1997; Denney & Rapport, 2001). As with all 
therapies, however, treatment emergent symptoms can and do occur.  
Side effects associated with psychostimulant treatment are well documented in the literature 
and most fall into one of three categories: cardiovascular effects (i.e., heart rate, blood pressure), 
physical effects (i.e., weight and growth), and physical and behavioral complaints. Recent 
reviews indicate that cardiovascular and physical effects associated with psychostimulant therapy 
are usually transient, dose dependent, readily resolved by discontinuing therapy, and fail to 
remain significant in long-term follow-up studies (Rapport & Moffitt, 2002). Investigations of 
psychostimulant related physical and behavioral complaints, however, have generated renewed 
interest owing to the paradoxical effects reported in recent, better-controlled studies. For 
example, higher mean severity ratings of physical and behavioral complaints were reported by 
teachers for children under placebo relative to children under low MPH doses (Barkley, 
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McMurray, Edelbrock, & Robbins, 1990; DuPaul, Anastopoulos, Kwasnick, Barkley, & 
McMurray, 1996; Fischer & Newby, 1991). Parents also report that their children experience 
fewer physical and behavioral complaints such as daydreaming, irritability, anxiety and nail 
biting under MPH than placebo (Ahman et al., 1993).  
Two hypotheses have been proposed to account for the paradoxical findings: (a) that adult 
raters (parents, teachers) confuse some symptoms of the disorder such as daydreaming and 
staring with drug-related side effects (Fine & Johnson, 1993; Firestone, Monteiro Munsten, 
Pisterman, Mercer, & Bennett, 1998); and (b) that ratings under no medication conditions (i.e., 
baseline, placebo) reflect normal levels of physical and behavioral complaints for boys in 
general, or boys with ADHD in particular, that may occur less frequently as a function of 
treatment (Rapport, Moffitt, & Randall, 2002). Both hypotheses are possibly owing to the non-
specific nature of side effect rating scales. Most are designed to assess a wide range of possible 
symptoms rather than emergent symptoms associated with a specific pharmacological regimen.   
The rater confusion hypothesis can be addressed by examining the type of physical and 
behavioral complaints reported under no-drug conditions, and changes from this state that occur 
under placebo and active drug conditions. Treatment related decreases in only those physical and 
behavioral complaints that mimic core or secondary features of ADHD (e.g., inattentiveness, 
difficulty concentrating, staring, daydreaming), coupled with no change or a worsening of 
complaints not typically associated with the disorder (e.g., cardiovascular, gastrointestinal, and 
pseudoneurological symptoms) lends empirical support to the rater confusion hypothesis. 
Juxtaposition of the psychostimulant emergent symptom literature with extant literature 
concerning the occurrence of physical and behavioral complaints in samples of non-referred and 
clinically diagnosed children is needed to examine the latter hypothesis.  
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The occurrence of physical and behavioral complaints in community samples of non-
referred children and adolescents is well documented. For example, nearly half of the 540 
children and adolescents in a community sample attending 3rd through 12th grade reported at least 
one physical symptom during the preceding two weeks (Garber, Walker, & Zeman, 1991), with 
the highest frequency of complaints involving headaches (25%), low energy (23%), sore muscle 
(21%), and abdominal discomfort (17%). Literature reviews confirm that headaches represent the 
most commonly reported painful physical and behavioral symptom, and occur in 10% to 30% of 
community samples of children on at least a weekly basis (Campo & Fritsch, 1994). 
Epidemiological studies corroborate these findings, wherein 50% to 80% of children report some 
type of headache within the past year (Barea, Tannhauser, & Rotta, 1996), and upwards to 15% 
experience headaches of a migrainous nature (Abu-Arefeh & Russell, 1995). Recurrent 
abdominal pain is also common (i.e., 10% to 25% of school-age children and adolescents), and 
nearly 15% of children complain of daily fatigue (Apley, 1975; Garber et al., 1991; Linna, 1991). 
Other physical and behavioral complaints commonly reported by children include 
musculoskeletal pain, back pain, and dizziness (Campo & Fritsch, 1994).  
Physical and behavioral complaints in children are not limited to Western culture (cf. 
Belmaker, Espinoza, & Pogrund, 1985), and extant evidence suggests that the frequency and 
type of physical and behavioral complaints vary with age and gender (Last, 1991). For example, 
recurrent abdominal pain appears to be more common in early childhood, whereas headache, 
limb pain, and polysymptomatic somatization in general increases with age (Achenbach, 1989).  
Psychiatric disability confers additional risk for physical and behavioral complaints. Twenty 
to 69% of children and adolescents with at least one psychiatric diagnosis experience physical 
and behavioral complaints (Egger, Costelo, & Angold, 1999; Masi, Favilla, Millepiedi, & Mucci, 
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2000; Taylor, Szatmari, Boyle, & Offord, 1996), particularly children with anxiety disorders. 
Children with panic disorder and separation anxiety are significantly more likely to complain of 
physical and behavioral symptoms than children with other primary anxiety diagnoses or 
depression (Last, 1991); however, physical and behavioral complaints are also prominent in 
children with depression (Carlson & Kashani, 1998, Pine, 2002; Ryan, Puig-Antich, Ambrosini, 
& Rabinovich, 1987). Children with externalizing disorder are also at greater risk than non-
psychiatric controls for physical and behavioral complaints. Boys with conduct disorder report 
twice as many headaches as boys without the disorder, and ADHD is associated with more 
frequent complaints of stomach aches (Egger et al., 1999), polydypsia, and polyuria (Mitchell, 
Aman, Turbott, & Manku, 1987) relative to non-psychiatrically disabled children.  
Collectively, the physical and behavioral complaint literature indicates that moderate to 
elevated physical and behavioral complaints consisting of headache, low energy, sore muscles, 
abdominal discomfort, daily fatigue, musculoskeletal pain, back pain, and dizziness are common 
among children, and that a diagnosis of ADHD confers potentially additive risk for 
stomachaches, polydipsia, and polyuria. These findings suggest that a substantial number of 
physical and behavioral complaints attributed to medication in past studies may have been 
confounded with high base rate occurrences of these behaviors in children with ADHD. This 
hypothesis can be examined by comparing base rate occurrences of physical and behavioral 
complaints with those reported under placebo and active medication conditions. A stable or 
decreasing frequency of complaints under placebo and active medication conditions relative to 
baseline levels supports the pre-existing/normal level complaints hypothesis.  
Other types of emergent symptoms specific to MPH therapy (e.g., cardiovascular symptoms, 
upset stomach, reduced appetite), other than those commonly reported by children or potentially 
5 
                                                                                    
confused core and secondary symptoms of ADHD, may worsen as a function of increasing MPH 
dose. These can be extracted from side effect rating scales and examined separately to determine 
whether changes in frequency occur as a function of expectancy (placebo) or active drug over 
and above base rate levels.   
The purpose of the present study was to examine several factors that may account for 
reported reductions in physical and behavioral complaints in children with ADHD as a function 
of psychostimulant therapy. Rival hypotheses concerning paradoxical effects associated with 
psychostimulant therapy and physical and behavioral complaint occurrence in children with 
ADHD were examined using a large sample of children with ADHD, and evaluated in the 
context of a double-blind, placebo-controlled, within subject (crossover) experimental design.  
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CHAPTER TWO: METHODOLOGY 
Participants 
One hundred thirty-four children were screened for inclusion in the study based on referrals 
from psychiatrists, pediatricians, and school personnel over a 5-year period. All children and 
their parents participated in a detailed, semi-structured clinical interview with the clinic’s 
supervising psychologist (M.D.R.). The interview was adapted from the Schedule for Affective 
Disorders and Schizophrenia for School-Age Children (Kaufman et al., 1997) and reviewed 
symptoms associated with disorders usually evident in childhood and adolescence as outlined in 
the DSM-III (American Psychiatric Association, 1980). Children were required to meet the 
following inclusion criteria: (1) an independent diagnosis by the child’s referring physician and 
the Children’s Learning Clinic (CLC) clinical psychologist (M.D.R.) using DSM-III criteria for 
ADDH; (2) a maternal report of a developmental history consistent with ADDH and problems in 
at least 50% of the situations on Barkley’s (1990) Home Situations Questionnaire; (3) a maternal 
rating of at least 2 standard deviations above the mean for the child’s age on the Werry-Weiss-
Peters Activity Scale (Routh, Schroeder, & O’Tauma, 1974); (4) a teacher rating of at least 2 
standard deviations above the mean on the Abbreviated Conners Teacher Rating Scale (ACTRS) 
(Conners, 1990); and (b) absence of any gross neurological, sensory, or motor impairment as 
determined by pediatric examination.  
Sixty-five children (58 boys, 7 girls) met criteria and participated in the study after written 
informed consent was obtained from their parent. Selected children were between 6 and 11 years 
of age (mean age = 8.56) and fell within the average range of intelligence (mean = 102.8; SD = 
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10) based on the Peabody Picture Vocabulary Test–Revised, Form L (Dunn & Dunn, 1981). All 
participants were Caucasian and from families of low to middle socioeconomic status 
(Hollingshead, 1975). Eight had experienced brief trials of psychostimulant within the past 4 
years.  
All children were considered pervasively hyperactive as judged by clinical interview and 
rating scale scores. A systematic review using current diagnostic nomenclature indicated that 
each of the 65 children would currently be classified as meeting criteria defining ADHD 
combined type, as detailed in the DSM-IV (American Psychiatric Association, 1994). The 
clinical outcome of these children has been reported elsewhere (Rapport et al., 1994) and the 
ADHD moniker will be used throughout this report. 
Many of the children showed symptoms of but did not meet formal criteria for mood and 
anxiety disorders. As a result, findings of this study may not generalize to children comorbid for 
ADHD and anxiety or affective disorders. Comorbidity for oppositional defiant disorder was not 
assessed because of the controversial nature of the disorder at the time the study was initiated. 
All selected children were attending regular elementary school classrooms, although several 
received concurrent special education services. Learning disabilities were not specifically 
assessed.  
Thirty-one of the 69 nonparticipating children met criteria and were enrolled in an 
abbreviated placebo-controlled medication trial (5 to 15 mg of MPH) during the first year of the 
clinic’s operation and are not reported here. Insufficient data were available for 2 children 
because of school conflicts, and 1 child moved out of state before completing the study. Side 
effect ratings were not obtained for the first 11 children participating in the 5-20 mg medication 
trials because the procedure was implemented late in the second year of the clinic’s operation. 
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The remaining 24 children scored within the established range for inclusion on the various rating 
scales, but their developmental histories were inconsistent with DSM-III criteria (i.e., onset of 
symptoms later than age 7 and/or duration less than 6 months). Fourteen of these children met 
criteria for conduct disorder, seven showed symptoms of anxiety disorder (1 social phobia, 6 
separation anxiety disorder), one had an eating disorder, and two were referred for neurological 
evaluation because there was evidence of a seizure disorder. 
Experimental Design and Procedures 
Drug administration. A double-blind, placebo-controlled, within-subject (crossover) 
experimental design was used in which ADHD children received a placebo and each of four 
active MPH doses after baseline assessment. Order of dose administration was counterbalanced 
and determined by random assignment such that an equal number of children received each dose 
during a given week of the study. MPH was prescribed by each child’s physician in the 
following doses: placebo, 5 mg (range = .10 to 0.26 mg/kg), 10 mg (range = 0.20 to 0.52 mg/kg), 
15 mg (range = 0.29 to 0.79 mg/kg) and 20 mg (range = 0.39 to 1.1 mg/kg). Fixed doses were 
used to reflect typical pediatric practice and because response to MPH is independent of body 
mass (Rapport & Denney, 1997; Swanson, Cantwell, Lerner, & McBurnett, and Hanna, 1991). 
MPH and placebo doses were packaged in colored gelatin capsules by the clinic’s pharmacist to 
avoid detection of dose and taste. Capsules were sealed in individual, daily envelopes to help 
control for accurate administration. 
After baseline data collection (first week), parents were given 1 week’s medication in 
predated envelopes at a single dose level (i.e., placebo, 5 mg, 10 mg, 15 mg, or 20 mg). Single 
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morning doses (as opposed to twice per day) were administered to maintain experimental 
control, as it was not possible to ensure that medication would be appropriately administered at 
school at an established time during the day. This procedure continued until each child received 
every dose for 6 consecutive days. All weekly dose changes occurred on Sundays (i.e., no 
capsules were administered on Saturdays) to allow for “washout” and to control for possible 
rebound effects. Parents were instructed to give their child a capsule each morning, one half hour 
before breakfast. Both used and unused envelopes were returned on a weekly basis to control for 
medication compliance. Medication was properly administered nearly 100% of the time. 
“Makeup” observation days were scheduled in 4 cases when compliance was not obtained.  
Procedures 
Parents and children completed the Subjective Treatment Emergent Symptoms Scale 
(STESS; Guy, 1976) during baseline, placebo, and each of the MPH conditions. The STESS was 
initially devised for adult raters and consists of questions concerning the occurrence and severity 
of a broad range of possible physical and behavioral complaints and emergent symptoms 
associated with pharmacotherapy. A child version was created using the same items (exceptions 
noted below), but reworded to ask children whether they had experienced a particular problem 
within the past three days, and if so, the degree of severity using the original version's 4-point 
response format (“not at all,” “just a little,” “pretty much,” “very much”). The original format of 
the STESS included several potential physical and behavioral complaints that would be difficult 
to interpret in terms of directionality, such as whether a child experienced problems with eating, 
drinking, or bowel movements (i.e., it would be unclear whether the child was eating more or 
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less, drinking more or less, or having more or fewer bowel movements). To reduce ambiguity, 
these items were reworded to include a directional outcome (e.g., During the past three days did 
you feel more thirsty?). The revised child version included a total of 63 questions.  
Parents were asked to complete the scale during each weekly visit throughout the study. The 
outcome reflected the physical and behavioral symptoms for the preceding week. Children were 
administered the scale during each weekly visit by trained graduate research assistants who read 
each item aloud to the child and recorded their verbal response. Graduate assistants were blind 
concerning children’s medication status. Completed questionnaires reflected physical and 
behavioral complaints experienced by children within the past three days and associated with a 
single experimental condition (baseline, placebo, or one of the four MPH conditions). 
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Table 1: Summary of symptoms included in STESS scale that may reflect Core/Secondary 
symptoms of ADHD. 
Parent 
Clumsiness 





Difficulty with attention 
More talkative 
Difficulty with sports 
Difficulty with parent relationships 




                                                                                    

















                                                                                    


















Difficulty with balance 




More bowel movements 
Fewer bowel movements 
Harder bowel movements  
Softer bowel movements 










Difficulty with harder words 
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Table 3 (continued) 
Parent Child 
Shaky hands  
--- 
More bad dreams 








More repetitive behaviors 
More self-harm behaviors 
Feeling “worse” 
More shaky  
Harder to do things with hands 












Note. Dashes indicate item was not included in the questionnaire. 
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CHAPTER THREE: RESULTS
 A three-tier data analytic strategy was used to examine the study’s two primary 
hypotheses: (a) rater confusion (i.e., that adult raters confuse some features of ADHD with drug 
related side effects); and (b) that baseline/placebo measures reflect normal levels of physical and 
behavioral complaints for boys in general or children with ADHD in particular. Children and 
parents completed the Subjective Treatment Emergent Symptoms Scale (STESS; Guy, 1976) 
during baseline, placebo, and each of the MPH conditions. All data was grouped into the 
following physical and behavioral complaint categories: (a) descriptions of physical and 
behavioral complaints related to core and secondary features of ADHD (Ahman, et al., 1993; 
Barkley et al., 1990; Beidel et al., 1991; DSM-IV, 1994) (see Table 1); (b) descriptions of 
physical and behavioral complaints common to pediatric age children (Belmaker et al., 1985; 
Campo et al., 1994; Garber et al., 1991), including those frequently reported by children with 
ADHD not receiving psychostimulant therapy (Egger et al., 1999; Mitchell et al., 1987) (see 
table 2); and (c) physical and behavioral complaints commonly reported in children receiving 
MPH treatment (e.g., nausea/upset stomach, dry mouth, decreased appetite) (see Table 3).  
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Tier I Analysis: Rater Confusion Hypothesis 
Parent reports of physical and behavioral complaints in the symptom category that mimics 
core/secondary features of ADHD were analyzed using a within subjects (parents) x 6 
(conditions: baseline, placebo, 5 mg, 10 mg, 15 mg, 20 mg) repeated measures analysis of 
variance (ANOVA). The analysis examines the hypothesis that adult raters confuse ADHD 
core/secondary features as MPH side effects. A p-value of .05 was used to evaluate significance 
for all analyses. The main effect for drug condition was significant [F (5, 640) = 16.34, p<.001].  
Post hoc analysis using Tukey’s HSD revealed that parent endorsement of physical and 
behavioral complaints that mimic secondary/core ADHD features under baseline were 
significantly higher than complaints endorsed under placebo and all active medication conditions 
(all p-values<.05). Significant differences were also found between placebo and the four MPH 
conditions (all p-values<.05). No significant differences emerged among the four MPH doses 
(see Figure 1).  
17 

























BL PL 5 mg 10 mg 15 mg 20 mg
MPH Dose
   










Figure 1: Mean severity ratings of physical and behavioral complaints in core and secondary 
features of ADHD category endorsed by parents under baseline, placebo, and methylphenidate 
conditions. 
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Analysis of trend was performed to examine the shape of the relationship between parent ratings 
of physical and behavioral complaints and MPH dose. Parent endorsements under baseline and 
active medication conditions were examined in the initial analysis (i.e., the placebo condition 
was excluded). The ensuing analysis was conducted using placebo and active drug conditions 
with baseline excluded. (Note: a basic assumption of trend analysis is that “level” of 
experimental conditions be of similar magnitude, which precludes simultaneous use of baseline 
and placebo in the same analysis). The proportion of treatment variance (R2 trend) was computed 
for each significant trend to determine the relative contribution of each trend component (e.g., 
linear, cubic, quadratic) when more than one component reaches statistical significance (Keppel, 
1991).  
 
Table 4: Trend Analysis for Symptoms Found in the Core Symptom Category  
 FLinear R2Linear FQuadratic R2Quadratic FCubic R2Cubic
Base-MPH 37.83** 0.15 20.77** 0.06 9.31* 0.00 
Placebo-MPH 12.35* 0.05 2.36 0.01 2.05 0.01 
Note. Base = baseline (no drug condition). MPH = methylphenidate. Base-MPH = trend analysis 
using baseline and active methylphenidate conditions. PL-MPH = trend analysis using placebo 
and active methylphenidate conditions. R2 = proportion of variance accounted for by trend 




                                                                                    
Trend analysis of parent endorsement of physical and behavioral complaints excluding the 
placebo condition (i.e., baseline, 5 mg, 10 mg, 15 mg, 20 mg) revealed significant linear [F (4, 
256) = 37.83, p<.001], quadratic [F (4, 256) = 20.77, p<.001], and cubic [F (4, 256) = 9.31, 
p<.001] trends. The linear trend accounted for the greatest proportion of variance (15%), whereas 
6% and 3% of variance was accounted for by the two higher-order trends (see Table 4 for R2 
values). This finding indicates that physical and behavioral complaints reported by parents that 
mimic core/secondary features of the disorder evidence a moderately abrupt decrease between 
baseline and MPH 5-mg, with minimal variation in frequency under higher dose conditions (see 
Figure 1). Only the linear trend was significant for the placebo-active drug trend analysis [F (4, 
256) = 12.35, p<.001], and the small proportion of variance accounted for (5%) indicates that the 
primary change in complaint frequency results from changes between baseline and active drug 
conditions.  
Collectively, the preceding analysis indicates a significant reduction in parent reports of 
physical and behavioral complaints that mimic core/secondary ADHD features under placebo 
relative to baseline, and under active MPH conditions relative to both baseline and placebo, with 
no significant variation in complaint frequency among active drug conditions. These findings are 
consistent with the hypothesis that adult raters confuse some features of ADHD as related side 
effects. 
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Tier II Analysis: Preexisting /Normal Level Hypothesis 
Parent and child reports of physical and behavioral complaints common to pediatric age 
children were analyzed using a 2 (child and parents raters) x 6 (conditions: baseline, placebo, 5 
mg, 10 mg, 15 mg, 20 mg) repeated measures analysis of variance (ANOVA) to examine the 
preexisting/normal level hypothesis. This hypothesis posits that the myriad everyday physical 
and behavioral complaints commonly reported by children (including those with ADHD) must 
be accounted for by examining baseline frequency/severity rates to separate them from actual 
treatment emergent symptoms associated with MPH.   
The rater by drug condition interaction [F (5, 640) = 2.22, ns] and main effect for rater [F (1, 
128) = 2.84, ns] were not significant, however, the main effect for drug condition was significant 
[F (5, 640) = 4.42, p<.001]. The decrease in endorsements from baseline to placebo (p<.05) and 
all active MPH conditions (all p-values <.05) is due primarily to decreased child endorsements 
albeit insufficient to produce a rater main effect or interaction. Mean child and parent 
endorsements of physical and behavioral complaints common to children under baseline, 
placebo, and the four MPH conditions are depicted in Figure 2.  
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Figure 2: Mean severity ratings parent and child endorsements of physical and behavioral 




                                                                                    
Tier III Analysis: Side Effects Commonly Attributed to Psychostimulant Treatment 
Parent and child reports of physical and behavioral complaints commonly attributed to 
psychostimulant therapy (true emergent symptoms) were analyzed using a 2 (child and parents 
raters) x 6 (conditions: baseline, placebo, 5 mg, 10 mg, 15 mg, 20 mg) repeated measures 
analysis of variance (ANOVA). The rater by drug interaction [F (5, 640) = 2.94, p<.05] and main 
effect for drug were significant [F (5, 640) = 10.66, p<.001]. There was no significant rater main 
effect [F (1, 128) = .099, ns].  
Post hoc analysis using Tukey’s HSD indicated that children endorsed significantly higher 
severity rates of physical and behavioral complaints commonly attributed to psychostimulants 
under baseline relative to placebo and all four active MPH conditions (all-p values < .05), and 
under placebo relative to 5-mg, 15-mg, and 20-mg conditions (p<.05). No significant differences 
emerged among the active MPH conditions. Parent endorsements showed a similar pattern of 
results – significantly more physical and behavioral complaints were reported under baseline 
relative to 5-mg and 20-mg MPH (all p-values<.05).  No other contrasts were significant.  
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Figure 3: Mean severity ratings of parent and child endorsements of physical and behavioral 
complaints in the category of emergent symptoms commonly attributed to methylphenidate 




                                                                                    
Collectively, these results indicate that the significant interaction effect was due to initially 
higher child relative to adult complaint endorsements under baseline, coupled with lower 
complaint severity under higher doses. Trend analysis results are summarized in Table 5 and 
reveal that child ratings are best characterized by a linear decrease in physical and behavioral 
complaints, with the largest decrease occurring between baseline and active medication 
conditions. Parent ratings are best characterized by a cubic decrease in complaints that accounts 
for less than 2% of change – indicating minimal change across the experimental conditions. 
 
Table 5: Trend Analysis for Symptoms that are considered "Emergent" or True Side Effects of 
Medication. 
 FLinear R2Linear FQuadratic R2Quadratic FCubic R2Cubic
Child       
Base-MPH 26.82** 0.11 6.23* 0.03 8.94* 0.02 
Placebo-MPH 6.25* 0.03 0.02 0.00 1.42 0.00 
Parent       
Base-MPH 2.57 0.01 1.27 0.00 4.05* 0.02 
Placebo-MPH 0.56 0.00 0.11 0.00 2.28 0.01 
Note. Base = baseline (no drug condition). MPH = methylphenidate. Base-MPH = Trend analysis 
using baseline and active methylphenidate conditions. PL-MPH = Trend analysis using placebo 
and active methylphenidate conditions. R2 = proportion of variance accounted for by trend 
components.  * = p < .05; ** = p < .001.  
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CHAPTER FIVE: CONCLUSION 
The present study examined competing hypotheses that may help explain past reports of 
paradoxical reductions in physical and behavioral complaints associated with MPH therapy in 
children with ADHD. Symptoms on the STESS side effect rating scale were separated into 
specific categories to investigate predictions that some physical and behavioral complaints 
represent ADHD primary/secondary features, whereas others reflect non-medication related 
complaints reported by children in general, or true emergent symptoms specific to 
psychostimulant treatment.  
Parent and child endorsements of physical and behavioral complaints showed significant 
reductions from baseline to active MPH conditions for all three categories, and were of a 
sufficient magnitude to be considered clinically meaningful (i.e., range = 27% to 62%). 
Significant reductions in symptom endorsements were also observed between placebo and active 
MPH conditions for parent ratings that reflect ADHD core/secondary features (e.g., sitting still, 
difficult peer relationships), and for child symptom ratings specific to MPH treatment (e.g., 
stomachaches, reduced appetite). These changes were smaller in magnitude than those observed 
for the baseline-MPH contrasts, and indicate that part of the observed effect is associated with 
expectancy or other factors related to placebo phenomena. No significant differences emerged 
among the four active MPH doses for child and parent endorsements across the three categories. 
  Our results are consistent with those reported in past studies that included baseline 
measures of psychostimulant effects. For example, Ahman and colleagues (1993) reported 
reduced frequencies in four behavioral symptoms assessed by the Stimulant Drug Side Effects 
Rating Scale (Barkley, 2005) under their high dose MPH condition (dose range = .3 mg/kg to .6 
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mg/kg). Efron, Jarman, and Barker (1997) reported similar results -- a decrease in frequency and 
severity of “side effects” relative to baseline when comparing MPH to dexamphetamine at .3 
mg/kg and .15 mg/kg, respectively. Placebo-controlled dose-response investigations without 
baseline measures report similar findings (e.g., Firestone, et al., 1998; Fischer & Newby, 1991). 
Collectively, these findings suggest that several items included on emergent rating scales likely 
reflect behavioral phenotypical features of ADHD rather than true emergent symptoms related to 
MPH therapy. Parent and teacher ratings of these scale items have previously been attributed to 
“rater confusion,” however an equally plausible explanation is that raters are accurately 
reflecting observed behavior changes in the children consistent with the vast literature on 
psychostimulant response, and investigators have misinterpreted these ratings by relying on total 
rather than item or factor scale scores. This holds even for scales developed specifically to 
monitor emergent symptoms associated with psychostimulant therapy, such as the Stimulant 
Drug Side Effects Rating Scale (Barkley, 2005), which contains multiple items that mirror core 
and secondary features of ADHD (e.g., trouble sleeping, proneness to crying, daydreams).  
Children’s complaints of physical discomfort on a weekly and reoccurring basis are well 
documented in the literature (Eggers et al., 1999; DuPaul, et al., 1996; Mitchell et al., 1987). Our 
results corroborate extant research in demonstrating that children with ADHD share this 
propensity for experiencing weekly discomfort such as headaches, feeling tired, muscle aches, 
stomachaches, and occasional dizziness under no-medication conditions. The results provide a 
compelling rationale for recognizing that children, like adults, experience daily physical 
discomfort that must be recognized and accounted for prior to initiating a medication trial. An 
unexpected result, however, was the significant decrease in these complaints under placebo and 
MPH conditions relative to baseline by child endorsements. Mean child complaint severity 
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decreased 44% to 56% from baseline to active MPH conditions. A proportion of this change 
appears to be related to expectancy effects associated with placebo phenomena in child ratings 
(i.e., changes from baseline to placebo for child ratings was 52%). These effects are traditionally 
attributed to a person’s belief in a treatment’s potential efficacy, but may also be mediated by 
changes in emotional state, perception, and behavioral improvement (Stewart-Williams, 2004).  
Placebo effects, however, only partially account for the significant reductions in complaints 
from baseline to MPH. The additional reduction in children’s endorsements may reflect 
improvement in associated areas of daily functioning, such as improved attention, academic 
performance, and classroom conduct (e.g., DuPaul & Rapport, 1993; MTA Cooperative Group, 
1999; Pelham et al., 1990). This explanation merits consideration and requires a carefully 
designed protocol to determine whether improved behavioral and/or academic functioning serve 
as significant mediators for children’s emergent symptoms.  
Similar results were evidenced when examining child endorsement of symptoms highly 
specific to psychostimulant medication. Children endorsed a significantly higher severity of 
complaints for this category under baseline relative to placebo (a 34% decrease) and all four 
active MPH conditions (decreases between 43% and 59%); and under placebo relative to 5-mg 
(25% decrease), 15-mg (31% decrease), and 20-mg (38% decrease) conditions. Parent 
endorsements showed fewer significant contrasts, with higher severity of physical and behavioral 
complaints reported under baseline relative to 5-mg (28% decrease) and 20-mg (27% decrease) 
MPH conditions only. Group-level analysis was supplemented by examination of individual 
child rating scale results, and revealed moderate increases in select emergent symptoms for some 
children (e.g., feeling sick to stomach, n = 11; skin itching, n = 11; dry mouth, n =8; less 
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urination, n = 8; appetite reduction, n =7, and less bowel movements, n = 7) under the two 
highest doses (i.e., 15-mg and 20-mg).  
Although all three classes of potential emergent symptoms showed significant decreases 
from baseline levels, several caveats merit consideration. Increased frequency and/or severity of 
emergent symptoms reported by or observed in children receiving psychostimulant therapy are 
probable to the extent that dosing regimens differ from the parameters reported herein, 
particularly in the symptom category highly specific to MPH. That is, children receiving multiple 
doses per day, single doses exceeding 20-mg, and over a longer duration of time are likely to 
experience a higher frequency and/or severity of emergent symptoms (Gadow, 1986). Preschool 
children with ADHD (Connor, 2002; Kollins, 2004), and those whose presentation includes other 
clinical features such as developmental delays (Aman, Marks, Tubott, Wilsher, & Merry, 1991; 
Handen et al., 1992), may also experience a higher frequency and/or severity of psychostimulant 
related emergent symptoms. A final caveat involves the applicability of group-level results for 
titrating and monitoring psychostimulant regimens for individual children. Generalization can 
never be assumed, and is always limited owing to the highly idiosyncratic treatment response 
observed within and across behavioral, cognitive, and emergent symptom domains in children 
with ADHD (Rapport & Kelly, 1991).  
Collectively, our findings point to a clear need to develop psychometrically sound 
treatment emergent symptom rating scales for purposes of monitoring physical and behavioral 
complaints in children treated with psychostimulants. Special care is warranted in wording scale 
items to ensure that their content differentiates between emergent symptoms and core/secondary 
symptoms of the disorder. This can be accomplished through extensive item refinement and 
submitting items to expert judges for review (see Clark & Watson, 1995). The development of a 
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separate factor scale that contains typical daily complaints endorsed by children based on extant 
research may also be desirable. Separating these complaints from drug related emergent 
symptoms affords practitioners improved ability to assess the extent of a child’s usual complaint 
frequency and severity, and to determine whether they change with treatment as evidenced 
herein. Inclusion of items that help differentiate improved attention from staring or constricted 
attention are also desirable (for a discussion of over-focused phenomena associated with 
psychostimulants, see Denny & Rapport, 2001). Finally, the administration of treatment 
emergent scales prior to initiating therapy must be considered a de rigueur component of clinical 
management for determining a true baseline picture of child complaints. 
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